Stock Track | Supernus Pharmaceuticals Soars 6.75% in Pre-market on Better-than-Expected Q4 Results and Strong Guidance

Stock Track02-25

Supernus Pharmaceuticals' stock surged 6.75% in pre-market trading following the release of its fourth-quarter financial results that exceeded analyst expectations and provided optimistic revenue guidance for 2026.

The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts polled by FactSet. Despite swinging from a profit of $0.27 per share a year earlier, the smaller-than-expected loss was viewed positively by investors.

Revenue for the quarter ended December 31 reached $211.6 million, significantly higher than the $174.2 million reported a year ago and surpassing the $195.2 million expected by analysts. The company also issued 2026 revenue guidance ranging from $840 million to $870 million, aligning closely with the $861.4 million analyst consensus estimate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139871397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139871397","market":"sg","top_or_hot":-1,"title":"Stock Track | Supernus Pharmaceuticals Soars 6.75% in Pre-market on Better-than-Expected Q4 Results and Strong Guidance","media":"Stock Track","content":"<p>Supernus Pharmaceuticals' stock surged 6.75% in pre-market trading following the release of its fourth-quarter financial results that exceeded analyst expectations and provided optimistic revenue guidance for 2026.</p><p>The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts polled by FactSet. Despite swinging from a profit of $0.27 per share a year earlier, the smaller-than-expected loss was viewed positively by investors.</p><p>Revenue for the quarter ended December 31 reached $211.6 million, significantly higher than the $174.2 million reported a year ago and surpassing the $195.2 million expected by analysts. The company also issued 2026 revenue guidance ranging from $840 million to $870 million, aligning closely with the $861.4 million analyst consensus estimate.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Supernus Pharmaceuticals Soars 6.75% in Pre-market on Better-than-Expected Q4 Results and Strong Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Supernus Pharmaceuticals Soars 6.75% in Pre-market on Better-than-Expected Q4 Results and Strong Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 19:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Supernus Pharmaceuticals' stock surged 6.75% in pre-market trading following the release of its fourth-quarter financial results that exceeded analyst expectations and provided optimistic revenue guidance for 2026.</p><p>The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts polled by FactSet. Despite swinging from a profit of $0.27 per share a year earlier, the smaller-than-expected loss was viewed positively by investors.</p><p>Revenue for the quarter ended December 31 reached $211.6 million, significantly higher than the $174.2 million reported a year ago and surpassing the $195.2 million expected by analysts. The company also issued 2026 revenue guidance ranging from $840 million to $870 million, aligning closely with the $861.4 million analyst consensus estimate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"","article_id":"1139871397","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139871397","pubTimestamp":1772018310,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Supernus Pharmaceuticals' stock surged 6.75% in pre-market trading following the release of its fourth-quarter financial results that exceeded analyst expectations and provided optimistic revenue...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"个股追踪|Supernus Pharmaceuticals盘前大涨6.75%，Q4业绩好于预期，指引强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Supernus Pharmaceuticals' stock surged 6.75% in pre-market trading following the release of its fourth-quarter financial results that exceeded analyst expectations and provided optimistic revenue guidance for 2026.The pharmaceutical company reported a Q4 loss of $0.07 per diluted share, which was better than the $0.08 loss anticipated by analysts polled by FactSet. Despite swinging from a profit of $0.27 per share a year earlier, the smaller-than-expected loss was viewed positively by investors.Revenue for the quarter ended December 31 reached $211.6 million, significantly higher than the $174.2 million reported a year ago and surpassing the $195.2 million expected by analysts. The company also issued 2026 revenue guidance ranging from $840 million to $870 million, aligning closely with the $861.4 million analyst consensus estimate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139871397","isCrawlerRequest":true}